Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Telegram Restored on Apple App Store After Temporary Removal 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
EXTON, Pa., April 10, 2018 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at the Alliance for Regenerative Medicine’s (ARM) 6th Annual Cell & Gene Therapy Investor Day on Tuesday, April 17 at 12:10 pm EDT in New York City and at the 2018 World Orphan Drug Congress USA on Wednesday, April 25 at 2:00 pm EDT in Oxon Hill, Maryland.
A live webcast of Fibrocell’s presentation at ARM’s Cell & Gene Therapy Investor Day will be available under the investor relations section of the Company’s website at www.fibrocell.com/investors/events and archived for 30 days.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact:
Karen Casey
484.713.6133
[email protected]
